Pluri Inc. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period
Pluri Inc. (PLUR) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period of 354.03 thousand shares for the 6-month period ending 2023-12-31, per its 10-Q filed 2024-02-12.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod · last filed 2024-02-12
- Pluri Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period for the quarter ending 2023-12-31 was 171.00K shares, a 61.72% increase year-over-year.
- Pluri Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period for the quarter ending 2023-09-30 was 183.03K shares, a 71.78% increase year-over-year.
- Pluri Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period for the quarter ending 2023-06-30 was 173.27K shares, a 12.17% increase year-over-year.
- Pluri Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period for the quarter ending 2023-03-31 was 175.30K shares.
- Pluri Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period for fiscal 2023 was 560.86K shares, a 11.12% increase from fiscal 2022.
- Pluri Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period for fiscal 2022 was 504.71K shares, a 4514.27% increase from fiscal 2021.
- Pluri Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period for fiscal 2021 was 10.94K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period 12 month as first filed |
|---|---|---|---|---|---|
| 2023-12-31 | 171.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-02-12 | 354.03K shares 10-Q · filed 2024-02-12 | 527.30K shares derived: sum of 3 quarters · filed 2024-02-12 | 702.60K shares derived: sum of 4 quarters · filed 2024-02-12 | |
| 2023-09-30 | 183.03K shares 10-Q · filed 2023-11-13 | 356.30K shares derived: sum of 2 quarters · filed 2023-11-13 | 531.59K shares derived: sum of 3 quarters · filed 2023-11-13 | 637.33K shares derived: sum of 4 quarters · filed 2024-02-12 | |
| 2023-06-30 | 173.27K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-09-12 | 348.57K shares derived: sum of 2 quarters · filed 2023-09-12 | 454.31K shares derived: sum of 3 quarters · filed 2024-02-12 | 560.86K shares 10-K · filed 2023-09-12 | |
| 2023-03-31 | 175.30K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-05-09 | 281.04K shares derived: sum of 2 quarters · filed 2024-02-12 | 387.58K shares 10-Q · filed 2023-05-09 | 542.05K shares derived: sum of 4 quarters · filed 2024-02-12 | |
| 2022-12-31 | 105.74K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-02-12 | 212.29K shares 10-Q · filed 2024-02-12 | 366.76K shares derived: sum of 3 quarters · filed 2024-02-12 | ||
| 2022-09-30 | 106.55K shares 10-Q · filed 2023-11-13 | 261.02K shares derived: sum of 2 quarters · filed 2023-11-13 | |||
| 2022-06-30 | 154.47K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-09-12 | 504.71K shares 10-K · filed 2023-09-12 | 45.00K shares 10-K · filed 2022-09-21 | ||
| 2022-03-31 | 350.24K shares 10-Q · filed 2023-05-09 | ||||
| 2021-06-30 | 10.94K shares 10-K · filed 2022-09-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B |